Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, a 39% increase driven by strong demand for Mounjaro and Zepbound. Reported earnings per share rose 16% to $7.22, while non-GAAP EPS increased 7% to $7.48. The company raised its full-year revenue guidance midpoint by $5.5 billion to the range of $91.0 to $92.0 billion and updated underlying non-GAAP EPS guidance to $35.00-$36.00. Regulatory progress included U.S. FDA approvals for Mounjaro, Onswik, Inluriyo, and an expanded indication for Jaypirca. Eli Lilly is a pharmaceutical company that develops and manufactures medicines for diabetes, obesity, oncology, immunology, and neuroscience.
